DIG
CGTX icon

Dauntless Investment Group’s Cognition Therapeutics CGTX Stock Holding History

Dauntless Investment Group’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$327K Sell
431,000
-35,000
-8% -$40.7K 0.22% 39
2025
Q4 		$629K Buy
+466,000
New +$756K 0.5% 30

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Dauntless Investment Group's CGTX Position: Q1 2026 in Review

Dauntless Investment Group reduced its Cognition Therapeutics (CGTX) stake by 7.5% in Q1 2026, selling an estimated $40.7K and leaving 431,000 shares worth $327K. The position accounts for 0.22% of the portfolio, ranked #39.

Dauntless Investment Group first reported a position in CGTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $629K in Q4 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Dauntless Investment Group held 431,000 shares of Cognition Therapeutics worth $327K as of Q1 2026.
  • Dauntless Investment Group sold 35,000 Cognition Therapeutics shares in Q1 2026, an estimated $40.7K.
  • Cognition Therapeutics made up 0.22% of Dauntless Investment Group's portfolio in Q1 2026, its #39 holding.
  • Dauntless Investment Group first reported a position in Cognition Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Dauntless Investment Group's Cognition Therapeutics position peaked at $629K in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Dauntless Investment Group's 13F filing for Q1 2026, filed 14 May 2026.